# Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

> **NCT02180217** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 137 (actual)

## Conditions studied

- Cushings Disease

## Interventions

- **DRUG:** osilodrostat
- **DRUG:** LCI699 matching placebo

## Key facts

- **NCT ID:** NCT02180217
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-06
- **Primary completion:** 2018-02-21
- **Final completion:** 2019-12-04
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02180217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02180217, "Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02180217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*